Skip to content

Domestic Policy Council, Staff Announcements

Trump has announced his Domestic Policy Team.

Andrew Bremberg, Director of the White House Domestic Policy CouncilAndrew Bremberg worked at the U.S. Department of Health and Human Services from 2001 to 2009, including serving as the Chief of Staff for the Office of Public Health and Science. He later served as Policy Advisor and Counsel on Nominations for Senator Mitch McConnell. He worked as the Policy Director for the 2016 Republican Party Platform. He now works in a lead policy and administrative role on the Presidential Transition Team. Mr. Bremberg received a J.D. from the Catholic University of America Columbus School of Law and a B.A. from the Franciscan University of Steubenville.

Paul Winfree, Deputy Director of the Domestic Policy Council and Director of Budget PolicyPaul Winfree was Director of the Thomas A. Roe Institute for Economic Policy Studies, the Center for Data Analysis and the Richard F. Aster Research Fellow, all at The Heritage Foundation. Prior to joining Heritage, Mr. Winfree was the Director of Income Security on the U.S. Senate Committee on the Budget. He has a Master of Science degree in economics and economic history from the London School of Economics and a Bachelor of Science degree in economics from George Mason University.

Katy Talento, Healthcare PolicyKaty Talento, an infectious disease epidemiologist with nearly 20 years of experience in public health and health policy, as well as government oversight and investigations and program evaluation, served on the campaign since July 2016. Ms. Talento has spent 12 years in the U.S. Senate, working for five Senators and two committees. A graduate of Harvard School of Public Health and the University of Virginia, she has also worked in the field on disease control programs in the U.S. and in Africa.

Ja’Ron Smith, Urban Affairs and RevitalizationJa’Ron K. Smith has served as a Congressional staff member for nearly a decade. Smith served the House Republican Conference legislative staff under then-Chairman Mike Pence prior to joining the Republican Study Committee to serve on the professional policy staff under Congressman Jim Jordan. He later served as Economic Advisor to Senator Tim Scott and currently works as the Director of External Affairs for Generation Opportunity. Mr. Smith was born in Cleveland, Ohio and is a double graduate of Howard University with a BBA in Finance and a Masters in Divinity.

Rob Goad, Education PolicyRob Goad currently serves on the Presidential Transition as the education lead for the implementation of the President-elect’s education policy agenda. Prior to developing education policy for the President-elect’s successful campaign, Mr. Goad served as a Senior Policy Advisor to House Policy Committee Chair Luke Messer focusing on education issues. He also played a pivotal role advancing school choice policies as Director of the Congressional School Choice Caucus. Mr. Goad received a bachelor’s degree in political science at Indiana University.

John Zadrozny, Justice and Homeland Security PolicyJohn Zadrozny has worked for the past six years on the House Committee on Oversight and Government Reform, the Senate Committee on Foreign Relations, and the Senate Committee on the Judiciary for Senator Ted Cruz. Prior to working on Capitol Hill, he served in the Office of National Drug Control Policy and the Department of State. Mr. Zadrozny has a J.D. from Catholic University’s Columbus School of Law in Washington, D.C. and a B.A. in History from Fordham University in Bronx, where he graduated magna cum laude.

Zina Bash, Regulatory Reform, Legal and Immigration PolicyZina Bash has held a variety of positions in business, law and government, and currently serves as the Executive Vice President of Operations and Business Development at Doctors’ Hospital at Renaissance. Her previous positions include Deputy Director of Policy and Communications for Senator Ted Cruz’s presidential campaign and Senior Counsel to the Senate Judiciary Committee in Senator John Cornyn’s office. Ms. Bash also practiced law as an appellate attorney at international law firm Gibson Dunn, & Crutcher LLP. Fluent in Spanish as a native speaker, she earned a bachelor’s degree from Harvard College, a J.D. from Harvard Law School and an M.B.A. from Wharton Business School. Ms. Bash also served as a law clerk to Justice Samuel Alito of the U.S. Supreme Court and Judge Brett Kavanaugh of the U.S. Court of Appeals for the D.C. Circuit.

Peter J. White, Senior Policy AnalystPeter White received his J.D. from American University’s Washington College of Law and has worked at the Federal Trade Commission and the Federal Communications Commission. Most recently, Mr. White served as Legislative Counsel for Congressman Mo Brooks. Licensed to practice law in the District of Columbia, Mr. White is an active member of the Federalist Society and performs pro bono legal work for the Washington Legal Clinic for the Homeless.

Additionally, the following team members are joining the Office of the Senior Advisor to the President for Policy, and will help to develop all policy and administer all functions underneath the umbrella of the Office, such as the formulation of a pro-worker agendaincluding support for affordable childcare and family initiatives.

Office of the Senior Advisor to the President for Policy, Staff Announcements:

Carlos Diaz-Rosillo, Director of Policy and Interagency CoordinationCarlos Diaz-Rosillo brings a wealth of experience on presidential power, administrative action, executive leadership and the policymaking and executive action process to this key role. Mr. Diaz-Rosillo has been serving on the President-elect’s Transition Team as Policy Implementation Executive Authority Advisor and White House Lead. He is fluent in Spanish, and graduated summa cum laude with degrees in International Relations (B.A.) and Civil Engineering (B.S.C.E) from Tufts University and Public Policy (M.P.P) and Government (A.M., PhD) from Harvard University, where he has been a member of the faculty of government for more than eight years.

Vince Haley, Advisor for Policy, Strategy and SpeechwritingVince Haley is a longtime associate of former U.S. House Speaker Newt Gingrich. He served as policy director and later campaign manager of Gingrich’s 2012 presidential campaign. Mr. Haley holds an undergraduate degree from the College of William & Mary, a law and Master’s degree from the University of Virginia, and a Master’s of law from the College of Europe. During the President-elect’s successful campaign, Mr. Haley developed ethics reform policies.

Ross Worthington, Advisor for Policy, Strategy and SpeechwritingRoss Worthington was a longtime aide to former U.S. House Speaker Newt Gingrich. He served as research director for Gingrich, deputy communications director for Gingrich’s 2012 presidential campaign and later as Gingrich’s primary writer. He is a graduate of Brown University, where he concentrated in Political Theory. During the campaign, Mr. Worthington, together with Mr. Vince Haley, worked to formulate and communicate policies that advanced the Trump agenda.

Ryan Jarmula, Advisor for Policy Development and SpeechwritingRyan Jarmula served as a member of Vice President-elect Mike Pence’s staff for a number of years. As a member of then-Congressman Pence’s Capitol Hill office, he handled a variety of issues including foreign affairs, and later served Pence in his capacity as Governor of the State of Indiana as Policy Director for Veterans Affairs and most recently as Speechwriter. During the campaign, Mr. Jarmula worked on Stephen Miller’s staff and had an active role in policy development. Mr. Jarmula is a graduate of Indiana University and completed his B.A. while majoring in political science in 2007.

Robert Gabriel, Special Assistant to the Senior AdvisorRobert Gabriel served as policy advisor on the President-elect’s campaign and assisted the National Policy Director in policy development, speechwriting functions, and staff management. He received a B.A. in Economics with a concentration in Policy from New York University.

Cures Passes House

Last night, the House approved, 392-26, the 21st Century Cures Act, amended by a Manager’s Amendment submitted by House Energy and Commerce Chair Fred Upton (R-MI). While the Manager’s Amendment modifies slightly the allocation of funding in the NIH Innovation Account on an annual basis, it maintains the overall level of funding in the Account at a total of $4.796 billion between FYs 2017 and 2026. For the Precision Medicine Initiative, the Amendment provides $1.455 billion between FYs 2017 and 2026; for BRAIN, $1.511 billion between FYs 2017 and 2026; for cancer research, $1.8 billion between FYs 2017 and 2023; and for clinical research to advance regenerative medicine using adult stem cells, the Amendment provides $30 million between FYs 2017 and 2020.

The overwhelming vote tally gained more Republican votes and registered the same level of Democratic support when compared to the vote on a previous 2015 bill version (HR 6).

The legislation now moves to the Senate for consideration next week.

White House Supports Cures

Late yesterday, the White House issued a Statement of Administrative Policy (SAP) in support of the 21st Century Cures legislation, which is on the House Floor today.

The SAP expressly calls out the Innovation Fund in the measure, which targets funding for several of the Administration’s health care priorities, as a highlight of the measure.

Read the SAP here. 

They’re BACK & 21st Century Cures to be Considered by the House

Congress is back today for the remainder of its lame-duck session. While both the House and Senate are slated to be in session until December 16, Republicans appear content to run out the clock until President-elect Donald Trump is sworn in on January 20, which could make for a much shorter and less eventful lame duck session.

Congress still has a handful of legislative priorities to take care of before the end of this Congress, including passing a final National Defense Authorization Act and a government funding bill. The final fiscal 2017 defense policy bill could surface as early as this week. Once finalized, a conference report must be signed by House and Senate negotiators before final floor consideration in both chambers.

The compromise NDAA is expected to ditch contentious riders, including provisions on the greater sage grouse and workplace protections based on sexual orientation. It’s also expected to include $9 billion on top of the Pentagon’s budget request, incorporating the Administration’s $5.8 billion war supplemental request the Obama Administration submitted to Congress on November 10, as well as funding to cover military readiness shortfalls.

It’s still all about the money.  

Additionally, Congress needs to pass a spending bill to fund government by the December 9 to avoid a shutdown. Republican leaders decided before Thanksgiving to move a new continuing resolution (CR) through March, allowing Trump to put his mark on federal spending during his first year in office. Meanwhile, Appropriators and Congressional leadership continue to wrestle with an exact date in March to end the CR as well as if to include the supplemental funding requested by the Obama Administration. 

Agenda for the Week

In the House, lawmakers will consider a compromise bill seeking to spur efforts on medical innovation. A new version of the 21st Century Cures measure (HR 6) emerged on Friday after private negotiations among bill supporters and is headed toward a House vote on Wednesday of this week. House Members passed the original bill in 2015, but Senators were unable to complete the assembly their own bill.

The newly revised version tweaks funding, offsets and other provisions of the package seeking to revamp Food and Drug Administration procedures for approving new drugs and boosting biomedical research efforts of the National Institutes of Health.

The main order of business on the Senate floor is a bill that would study expanding a program to provide specialized medical treatments to rural and medically underserved communities.

Compromise on Cures Heads to House

The House Rules Committee has noticed that 21st Century Cures will be considered next week. The package is expected on the House floor on Wednesday, November 30. The legislation is expected to be added as an amendment to an existing bill (H.R. 34) to allow for expedited action in the Senate. 

The House Rules Committee’s summary memo is 44 pages. The bill text is just under 1,000 pages. The package contains major provisions in the Cures and Senate Innovation packages, and the Mental Health Crisis Reform Act of 2016, (which includes Sections 9031 and 9032 on college mental health training and services grants and establishes interagency working group on mental health).

Generally

NIH is reauthorized until 2020 and the bill includes provisions intended to address the regulatory burden imposed on researchers, among other provisions. Rather than establish mandatory funding increases for NIH, appropriators would have to release (appropriate) funding each year to the Office of the Director.  The bill establishes a similar mechanism providing $500 million for initiatives at FDA for FYs 2018-2026, and $1 billion for the Secretary to provide to states in FYs 2017 and 2018 for opioid abuse prevention and response efforts.

There are limitations to the general funds going to the office of the Director. The bill also establishes an “Innovation Projects” account for specific initiatives at NIH and FDA, which are special limitations on the general appropriations going to the Office of the Director. For NIH, the bill provides a total of $4.796 billion for FYs 2017-2026 to the NIH director, including $1.4 billion for the Precision Medicine Initiative, $1.564 billion for the BRAIN Initiative, $1.802 billion for cancer research, and $30 million for clinical research to further the field of regenerative medicine using adult stem cells. 

The funding for the Innovation Fund is discretionary, but due to the phrasing in the legislation, monies the Innovation Fund does not count against the appropriators caps. However, the language essentially says that appropriations from the account are subtracted from the discretionary budget authority.  What’s more important is that both CBO and the Administration (the OMB specifically) agree that spending from the Innovation funds do not count against the caps and the language works the way described below. The money will be put in a specific fund every year for the appropriators to use specifically for NIH, FDA, Cancer Moonshot, etc. In lay terms, the funds can only be used for these purposes and every dollar must be used in the next 10 years. 

There are significant inclusions and some noticeable absences including:

  • Section 2034 – Reducing Administrative Burden for Researchers (p 66). This section contains several provisions to reduce administrative burdens on grants, including subrecipients, financial conflict of interest reporting, and reducing burdens on animal care and use in research. 
  • Section 202 – Supports young, emerging scientists by prioritizing policies and programs (p. 45). FY 2017 appropriations includes funds for a national Academies of Science study on improving opportunities for new researcher; and Strengthens NIH’s existing loan repayment programs by increasing the yearly loan repayment amount from $35,000 to $50,000 and streamlining the loan repayment categories.

The revised draft also includes bipartisan, House-passed legislation, the Helping Hospitals Improve Patient Care Act of 2016 (H.R. 5273), that contains several provisions related to socioeconomic status (SES) adjustment and off-campus hospital outpatient department (HOPD) site-neutral payment policy. 

To pay for this effort, the bill includes some of the offsets originally included in H.R. 6, including: 

  • Section 5009. Rescinds $3.5 billion for Prevention and Public Health Fund;
  • Section 5010. Directs the DOE to sell a portion of the Strategic Petroleum Reserve; 
  • Section 5011. Rescinds $464 million available to U.S. territories under ACA.